Data from: Polyphasic data support the splitting of Aspergillus candidus into two species; proposal of Aspergillus dobrogensis sp. nov.

Aspergillus candidus is a species frequently isolated from stored grain, food, indoor environments, soil and occasionally also from clinical material. Recent bioprospecting studies highlighted the potential of using A. candidus and its relatives in various industrial sectors as a result of their significant production of enzymes and bioactive compounds. A high genetic variability was observed among A. candidus isolates originating from various European countries and the USA, that were mostly isolated from indoor environments, caves and clinical material. The A. candidus sensu lato isolates were characterized by DNA sequencing of four genetic loci, and agreement between molecular species delimitation results, morphological characters and exometabolite spectra were studied. Classical phylogenetic methods (maximum likelihood, Bayesian inference) and species delimitation methods based on the multispecies coalescent model supported recognition of up to three species in A. candidus sensu lato. After evaluation of phenotypic data, a broader species concept was adopted, and only one new species, Aspergillus dobrogensis, was proposed. This species is represented by 22 strains originating from seven countries (ex-type strain CCF 4651T=NRRL 62821T=IBT 32697T=CBS 143370T) and its differentiation from A. candidus is relevant for bioprospecting studies because these species have different exometabolite profiles. Evaluation of the antifungal susceptibility of section Candidi members to six antifungals using the reference EUCAST method showed that all species have low minimum inhibitory concentrations for all tested antifungals. These results suggest applicability of a wide spectrum of antifungal agents for treatment of infections caused by species from section Candidi.亮白曲霉（Aspergillus candidus）是一种常见分离菌株，可从储粮、食品、室内环境及土壤中分离得到，偶尔也可从临床样本中分离获得。近期的生物勘探研究凸显了亮白曲霉及其近缘类群在多工业领域的应用潜力，因其可高效合成多种酶类与生物活性化合物。对采自欧洲多国及美国的亮白曲霉分离株进行分析后发现，其遗传变异性较高，这些分离株多来源于室内环境、洞穴及临床样本。研究通过对4个遗传位点开展DNA测序，对广义亮白曲霉（A. candidus sensu lato）分离株进行了鉴定，并探究了分子物种界定结果、形态学特征与胞外代谢物谱之间的一致性。经典系统发育分析方法（最大似然法、贝叶斯推断）以及基于多物种溯祖模型的物种界定方法均支持：广义亮白曲霉类群可划分为至多3个物种。在对表型数据进行评估后，研究采用了更宽泛的物种概念，仅正式提出1个新种——多布杰曲霉（Aspergillus dobrogensis）。该新种包含来自7个国家的22株菌株，其模式菌株（ex-type strain）为CCF 4651ᵀ=NRRL 62821ᵀ=IBT 32697ᵀ=CBS 143370ᵀ。该新种与亮白曲霉的区分对生物勘探研究具有重要价值，因二者的胞外代谢物谱存在显著差异。采用欧洲抗菌药物敏感性试验委员会（EUCAST）参考方法，对念珠菌组（section Candidi）成员的6种抗真菌药物敏感性进行了评估，结果显示所有受试物种对所有测试抗真菌药物的最低抑菌浓度均较低。上述研究结果表明，广谱抗真菌药物可用于治疗念珠菌组物种引发的感染。